Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential High-Dose Alkylating Agents in Metastatic Breast Cancer
NCT00002680Phase 2Completed
- Sponsor
- Yale University
- Start
- Feb 1994
- Primary completion
- Dec 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, melphalan and thiotepa in breast cancer, sponsored by Yale University. Primary endpoints: Feasibility of Sequential High-Dose Chemotherapy and Efficacy of Sequential High-Dose Chemotherapy. Started Feb 1994; status: completed.
02
Drugs
cyclophosphamidemelphalanthiotepa
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00002680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002680.